The proceeds from the Series A will be used to expand the business and operational structure of the company, including the opening of global corporate headquarters in the Greater Philadelphia Area, to advance the clinical development of its lead candidate KBP-5074, a mineralocorticoid receptor antagonist for cardiovascular disease entering Phase 2b; and to support other promising programs in the pipeline.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

116 Village Blvd. 210
Princeton, NJ 08540
USA

Phone

(609) 531-0889

Website

www.kbpbiosciences.com

Email Address

Not Recorded

Overview

KBP is a world-class biotechnology research & development organization dedicated to providing innovative therapies for unmet medical needs.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

Zhenhua Huang

Chief Executive Officer

Johan Spoor

Chief Financial Officer

Nick Hart

Vice President

James McCabe

VP - Bus. Development

Fred Yang

Browse more venture capital transactions:

Prev: 1/6/2018: TowerView Health venture capital transaction
Next: 1/6/2018: Genome Medical venture capital transaction

Share this article

About Our Venture Capital Transactions Database

Our team works diligently to report on every notable VC transaction. VC investment data records on this site come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary